Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR6002B
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR6002B is an investigational pharmaceutical agent studied as part of a combination therapy for the treatment of gastric and duodenal ulcers. It is being evaluated in clinical trials alongside related compounds, specifically BR6002 and BR6002A, to assess pharmacokinetics and safety under fed conditions in healthy adult volunteers. The drug is developed by Boryung Pharmaceutical (also known as Boryung Corp.). The precise mechanism of action, molecular target(s), and chemical structure have not been disclosed publicly. Current evidence suggests it is a small molecule drug intended for gastrointestinal indications such as duodenal ulcer and stomach (gastric) ulcer[1][4][5].
Beyond the preview
Go deeper on BR6002B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR6002B.